Company intelligence / Profile preview

PsyMood

Coconut Creek, Florida, United Statespsymood.com ↗

Ownership: Private
Development stage: Other

Overview

PsyBio Therapeutics has developed a proprietary biosynthetic platform to produce novel psychoactive compounds—primarily tryptamines—for the treatment of mental health conditions. The company has demonstrated laboratory-scale production, filed multiple patents, established academic collaborations with Miami University, and is preparing its first candidates for IND submission targeting cancer-related depression. No human clinical trial results have been reported yet.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeBiologicSynthetic oligonucleotidePeptides
Industry: Biotech

Partnerships

Miami University

Beyond the preview

Go deeper on PsyMood.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PsyMood.

Explore the full profile